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THE COST-EFFECTIVENESS OF PAROXETINE IN TREATMENT
OF MAJOR DEPRESSIVE DISORDER IN JAPAN
Nakahara N1, Kamae I2,Yanagisawa S2
1Kobe University,Tokyo, Japan; 2Kobe University, Kobe, Japan
OBJECTIVES: To assess the cost-effectiveness of paroxetine
(PX) compared with conventional tricyclic antidepressants
(TCA’s) for major depressive disorder in Japan. METHODS: A
decision analytic model was built in order to compare three reg-
imens: 1) initiating with PX followed by a TCA (PX-TCA’s); 2)
a TCA followed by PX (TCA’s-PX); and 3) TCA’s only. The deci-
sion tree incorporated the probabilities of dropping out of
therapy obtained from a meta-analysis of randomized controlled
trials in Japan, and also relapse or recurrence probabilities of
depressive symptoms employed from published literature.
Resource use and costs were estimated by the national health
insurance (NHI) scoring system. Health related quality of life
was incorporated in the model using utility values in the litera-
ture. The analysis was performed from a patient perspective
during nine months including the follow-up period. The sensi-
tivity analyses were conducted to test the robustness of the
results. RESULTS: The average costs per patient for each
regimen of the PX-TCA’s, the TCA’s-PX and the only TCA’s were
estimated with 4676€, 4541€ and 5045€, respectively. Regard-
ing the utility analysis, the PX-TCA’s best contributed to gain
with incremental cost-effectiveness ratio of 5587€/QALY. The
average cost per patient for each regimen of the PX-TCA’s or 
the TCA’s-PX remained lower than that of the only TCA’s over
the ranges of the sensitivity analyses. CONCLUSIONS: A treat-
ment for major depression using PX combined with TCA’s was
cost-saving in terms of average costs per patient, comparing to
the treatment by the TCA’s alone. The ﬁrst choice of PX did not
reduce the average cost towards the ﬁrst choice of TCA’s in the
combined treatment. When quality of life of patients incorpo-
rated, the ﬁrst choice of PX was best recommended among the
three strategies.
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THE HEATLH—RELATED QUALITY OF LIFE OF CHILDREN
SUFFERING FROM ADHD AND THE COSTS TO SOCIETY
Hakkaart L1, Zwirs B2, Buitelaar J3, Schulpen T2,Vlasveld L4,
Bouwmans C1, Rutten F1,Veraart C5
1Institute for Medical Technology Assessment, Rotterdam,
Netherlands; 2University Medical Center Utrecht, Utrecht,
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OBJECTIVES: The objective of this study is to estimate the
Health Related Quality of Life (HRQoL) of ADHD children and
the societal costs for The Netherlands. METHODS: An initial
population of 10,000 children aged 6–8 years were rated by their
schoolteachers to determine the probability of ADHD. A total
of 150 children with low scores (low probability) and 150 with
high scores were invited for a detailed prospective assessment of
the burden of illness for patient and relatives. We collected data
from the mother on health care utilization and HRQoL of 3 cat-
egories children, e.g. children in the community with high scores
(group 1), clinical ADHD children (group 2) and controls with
low scores (group 3), at 4 moments in time (baseline, t = 6
months, t = 12 months and t = 18 months). The Child Health
Questionnaire (CHQ-PF50) was used for measuring the
HRQoL. Additionally, health care utilization and productivity
loss of the mother of the respondents were assessed by using the
Trimbos and iMTA questionnaire on Costs associated with Psy-
chiatric illness’ (TiC-P). RESULTS: At baseline, we distributed a
total of 165 questionnaires for the 3 groups. The response rates
were; group 1: 94% (n = 33), group 2: 90% (n = 64) and group
3: 78% (n = 47) respectively. Of group 1, 33% of the respon-
dents were identiﬁed as ADHD by a paediatrician. Except for
physical function, group 2 (ADHD patients) scored signiﬁcant
worse on social and emotional functioning and the health care
costs were higher than group 1 and 3. CONCLUSIONS: Chil-
dren suffering from ADHD had worse HRQoL and higher health
care costs than the controls.
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ANNUAL SOCIETAL COSTS AND QUALITY OF LIFE IN
CHILDREN WITH NEUROPSYCHIATRIC DISORDERS IN
SWEDEN
Myren KJ1, Gillberg C2, Nydén A2
1Eli Lilly Sweden AB, Solna, Sweden; 2Göteborg University,
Gothenburg, Sweden
OBJECTIVES: The objective of the study was to calculate annual
costs in children with AS/HFA, ADHD and RD/WD, and to
explore which variables explained the variations in costs.
METHODS: Sixty boys—20 with high-functioning autism or
Asperger syndrome (AS/HFA), 20 with attention deﬁcit hyper-
activity disorder (ADHD) and 20 with reading and writing dis-
order (RD/WD)—participated in 1994 in an evaluation project
in Göteborg, Sweden. In 2003, a second follow up was under-
taken in 56 boys and their families. Cross sectional data on out-
patient and inpatient care for the child, and indirect resource use
for the families, e.g. time taken off from work and school assis-
tance was collected through questionnaires. Local unit costs and
prices were then applied to calculate annual costs. The parents
also ﬁlled out the Child Health Questionnaire (CHQ-PF50).
RESULTS: A total of 52 families responded to the question-
naires. The mean age was 18 years. The mean annual costs (SEK)
were 67,000, of which indirect costs were 62,500 and direct
costs 4500. Children with AS/HFA and ADHD had mean costs
of 89,800 and 86,500, compared to 23,400 in children with
RD/WD. Multiple regression analysis showed a strong correla-
tion between costs and the psychosocial summary score of the
CHQ: Total annual costs = 330,000 - 5800 ¥ PsS (r = -0.70).
Children with a PsS score below the median (47), had signiﬁ-
cantly higher total costs (SEK104,000 vs. 27,000) and indirect
costs (SEK97,000 vs. 24,000) than children with scores above
the median. CONCLUSIONS: These results emphasize that the
indirect costs in child neuropsychiatric disorders are signiﬁcant,
representing more than 90% of the total costs. The variation in
annual costs is explained, to a great extent, by psychosocial
impairments. The results indicate that a treatment, which
improves the psychosocial functioning of the child and family,
may have signiﬁcant potential in reducing family and societal
costs.
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TOTAL HEALTH CARE CONSUMPTION AND COSTS OF
SICKNESS FUND INSURED PATIENTS IN THE NETHERLANDS
Veraart C1, De Boo A2
1Lilly Nederland BV, Houten, Utrecht, Netherlands; 2Vektis, Zeist,
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OBJECTIVES: To estimate health care utilization and costs for
sickness fund insured patients receiving methylphenidate for
ADHD treatment in The Netherlands during 1999–2001.
METHODS: Retrospective analysis was conducted on a medical
and pharmacy claims database of the national sickness funds.
Patients using methylphenidate (MPH, n@13,000) were selected
